Injection of Autologous CD34-Positive Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia.

Trial Profile

Injection of Autologous CD34-Positive Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Autologous stem cell therapy (Primary)
  • Indications Angina pectoris; Myocardial ischaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Mar 2018 According to a Caladrius Biosciences media release, Douglas W. Losordo, MD, FACC, FAHA, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer of Caladrius is the principal investigator of the study
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top